← Eichor
Study identifier: NCT05124912 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

REMASTer: REcurrent Brain Metastases After SRS Trial

Condition: Brain Metastases · Radiation Necrosis · Recurrent Tumor  ·  Sponsor: Monteris Medical

PhaseNA
Planned participants261
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.

This description comes directly from the study's public registry record.

Talk to the study team

Christa Seligman  ·  952-463-7747  ·  cseligman@monteris.com

Kate Weed  ·  kweed@monteris.com

Always discuss trial participation with your own doctor first.

Locations (9)

UCLALos Angeles, California, United StatesRecruiting
University of ChicagoChicago, Illinois, United StatesRecruiting
University of MarylandBaltimore, Maryland, United StatesRecruiting
WashUSt Louis, Missouri, United StatesRecruiting
Duke University HospitalDurham, North Carolina, United StatesActive Not Recruiting
Wake Forest Baptist Medical CenterWinston-Salem, North Carolina, United StatesRecruiting
Cleveland ClinicCleveland, Ohio, United StatesRecruiting
Kettering HealthKettering, Ohio, United StatesRecruiting
Medical College of WisconsinMilwaukee, Wisconsin, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05124912